Development of a novel technology for in vitro evaluation of RNA/DNA-targeted compounds

细菌对现有抗菌剂的高适应能力是一个主要问题，需要在新型抗生素的设计中找到新的方法。其中一种方法是由加拿大一家小型高科技公司otava Ltd .采用的，它基于化学分子与特定细菌RNA或DNA序列的选择性结合。这种结合导致细菌生长和繁殖的枯竭。在这里，我们提出了一种新的化学筛选和评价化合物的方法，旨在选择性地结合微生物RNA/DNA。利用计算机模拟方法，Otava公司创建了新的精细有机化合物库，这些化合物与典型RNA/DNA靶标的物理和结构参数相匹配。进一步筛选旨在确定最有希望的前抗生素的步骤非常昂贵、耗时，并且需要特殊的生物危害认证实验室设施。目前，Otava公司需要与大型制药公司合作，对他们生产的每种化合物的活性进行体内筛选。这种方法大大增加了产品开发和发现商业化之间的周转时间。缺乏快速筛选方法来评估其化合物的活性，阻碍了它们的研究能力，限制了它们的生长能力。我们相信，我们将能够开发一种纯化学方法来估计文库中有机化合物作为特定细菌DNA序列复制选择性抑制剂的潜力。这将允许消除不太有效的化合物，并向制药工业提出高质量的竞争性商业产品。我们希望这能让这家安大略省的小公司成长起来，并与更大的国际公司竞争。众所周知，加拿大公司很难与第三世界国家竞争，这些国家过度使用廉价劳动力，并维持恶劣的工作环境，以降低产品成本。我们希望利用我们的科学优势，优化药物筛选的过程，让加拿大公司在保持高标准的工作环境和生活的同时，加强他们的研究力量。

The high adaptation ability of bacteria to existing antibacterial agents is a major issue that requires newapproaches in the design of novel antibiotics. One such approach, used by a small hi-tech Canadian companyOtava Ltd, is based on selective binding of chemical molecules to specific bacterial RNA or DNA sequences.This binding leads to depletion of bacteria growth and reproduction. Here we propose a new methodology forchemical screening and evaluation of compounds designed to selectively bind microbial RNA/DNA. Usingcomputer simulation methods, Otava Inc. has created novel libraries of fine organic compounds that matchphysical and structural parameters of typical RNA/DNA targets. Further screening steps aimed to determinethe most promising pre-antibiotics are very expensive, time-consuming, and require special biohazardaccredited laboratory facilities. For now, Otava Inc. needs to collaborate with large pharmaceutical companiesto perform in vivo screening of the activity of each compound they produce. This approach significantlyincreases the turnover time between the development of the product and commercialization of the findings. Thelack of the fast screening method to evaluate the activity of their compounds is hampering their researchabilities and limiting their ability to grow. We believe that we will be able to develop a purely chemical methodto estimate the potential of organic compounds from the library to act as selective inhibitors of duplication ofspecific bacterial DNA sequences. This will allow eliminating less effective compounds and proposing highquality competitive commercial products to the pharmaceutical industry. We expect this to allow the smallOntario company to grow and compete with larger international companies. It is not a secret that it is verydifficult for Canadian companies to compete with third-world countries that over-use cheap labor power andmaintain poor working environments to reduce the cost of their products. We want to use our scientificstrengths to optimize the process of pharmaceutical screening and allow Canadian companies to intensify theirresearch power while maintaining high standards of work environment and living.